Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtre
1.
J. bras. pneumol ; 50(4): e20240026, 2024. tab, graf
Article Dans Anglais | LILACS-Express | LILACS | ID: biblio-1569315

Résumé

ABSTRACT Objective: Thymidine-dependent small-colony variants (TD-SCVs) of Staphylococcus aureus are being isolated with increasing frequency from patients with cystic fibrosis (CF). The aim of this study was to evaluate the relationship between TD-SCV isolation and pulmonary function in patients with CF, as well as to determine whether the emergence of TD-SCVs was associated with trimethoprim-sulfamethoxazole (TMP-SMX) use and with coinfection with other microorganisms. Methods: This was a retrospective case-control study including patients with CF who visited the Clinical Hospital Complex of the Federal University of Paraná, in Curitiba, Brazil, between 2013 and 2022. Demographic, clinical, and spirometric data, as well as information on TD-SCVs and other isolated microorganisms, were collected from the medical records of patients with CF and TD-SCVs (TD-SCV group; n = 32) and compared with those of a matched group of patients with CF without TD-SCVs (control group; n = 64). Results: Isolation of TD-SCVs was positively associated with TMP-SMX use (p = 0.009), hospitalization (p < 0.001), and impaired pulmonary function (p = 0.04). Conclusions: The use of TMP-SMX seems to contribute to the emergence of TD-SCVs, the isolation of which was directly associated with worse pulmonary function in our sample.

2.
Rev. Soc. Bras. Med. Trop ; 51(5): 709-711, Sept.-Oct. 2018. graf
Article Dans Anglais | LILACS | ID: biblio-957463

Résumé

Abstract Ralstonia mannitolilytica, a Gram-negative bacterium, is rarely isolated in clinical laboratories. It has been associated with outbreaks due to its ability to survive in liquid media and hospital devices. We describe three cases of bacteremia caused by R. mannitolilytica in a neonatal intensive care unit in Curitiba, Southern Brazil. All isolates presented the same PFGE profile. The common source of infection was undetected in surveillance cultures for the outbreak survey. All patients received antimicrobial treatment and were discharged from the maternity. Due to the characteristics of the microorganism, clinicians and microbiologists should pay attention to the emergence of Ralstonia spp. infections.


Sujets)
Humains , Mâle , Femelle , Nouveau-né , Unités de soins intensifs néonatals , Infection croisée/microbiologie , Infections bactériennes à Gram négatif/microbiologie , Bactériémie/microbiologie , Ralstonia/isolement et purification , Brésil , Infection croisée/diagnostic , Infections bactériennes à Gram négatif/diagnostic , Bactériémie/diagnostic
3.
J. bras. patol. med. lab ; 38(3): 191-197, jul.-set. 2002. tab
Article Dans Portugais | LILACS | ID: lil-330642

Résumé

Há alguns anos tem-se verificado um aumento progressivo da resistência de alguns cocos gram-positivos a determinados antimicrobianos. Este aumento da resistência tem sido observado principalmente no ambiente hospitalar, e as bactérias mais comumente envolvidas são os Staphylococcus spp. e os Enterococcus spp. Devido a este fato, novos antimicrobianos são avaliados para o tratamento de infecções causadas por estas cepas multirresistentes. A associação quinupristina/dalfopristina (Q/D), também conhecida como Synercid©, é um antibacteriano da classe das estreptograminas, de uso endovenoso, composto por dois derivados semi-sintéticos da pristanamicina. A combinação das estreptograminas B e A na razão de 30:70 tem atividade antimicrobiana voltada para cocos gram-positivos, como Staphylococcus spp., Streptococcus spp., incluindo S. pneumoniae e Enterococcus faecium, sendo o E. faecalis habitualmente resistente. Neste estudo foi avaliada atividade in vitro de Q/D e outros oito antimicrobianos frente a 631 amostras de cocos gram-positivos isoladas de cinco centros brasileiros, complementadas com outras 20 cepas de E. faecium resistentes à vancomicina, provenientes dos Estados Unidos. Para a avaliação da sensibilidade aos antimicrobianos foi determinada a concentração inibitória mínima (MIC) pelo método do Etest (AB Biodisk, Solna, Suécia) e as cepas testadas foram: Staphylococcus aureus (n=267), Staphylococcus coagulase negativo (n=131), Streptoccus pneumoniae (n=130), Streptococcus beta-hemolíticos (n=28), Enteroccus faecalis (n=44) e E. faecium (n=51). A Q/D demonstrou excelente atividade contra Staphylococcus spp., independente de serem sensíveis ou resistentes à oxacilina. Para S. pneumoniae, a Q/D apresentou igualmente uma ótima atividade, inclusive para as cepas com resistência intermediária ou total para penicilina. Entre as cepas de E. faecium sensíveis à vancomicina, o MIC 90 de Q/D obtido foi de 3µg/ml, sendo que 45 por cento das cepas testadas foram sensíveis e 55 por cento apresentaram sensibilidade intermediária à associação. Desta forma, pode-se afirmar que a associação. Desta forma, pode-se afirmar que a associação Q/D representa uma nova opção para o tratamento endovenoso de infecções causadas por cocos gram-positivos, principalmente para as cepas multiresistentes, sendo também uma alternativa ao uso de glicopeptídeos


Sujets)
Antibactériens , Cocci anaérobies à Gram négatif , Association de médicaments , Spécificité d'espèce , Techniques in vitro , Tests de sensibilité microbienne , Multirésistance aux médicaments , Résistance microbienne aux médicaments , Amérique latine
4.
Braz. j. infect. dis ; 2(3): 160-3, Jun. 1998.
Article Dans Anglais | LILACS | ID: lil-243411

Résumé

We report a fatal case of septicemia due to a vancomycin-resistant Enterococcus faecium in a 9 year-old girl with aplastic anemia. The isolate was also resistant to amplicillin, teicoplanin, gentamicin (high level), and streptomycin (high level). We believe that this is the first case of vancomycin-resistant Enterococcus (VRE) reported from a clinical specimen in Brazil.


Sujets)
Humains , Femelle , Enfant , Anémie aplasique/diagnostic , Anémie aplasique/traitement médicamenteux , Antibactériens/usage thérapeutique , Bactériémie , Choc septique/mortalité , Enterococcus , Vancomycine/effets indésirables , Vancomycine/usage thérapeutique , Issue fatale , Infection croisée/prévention et contrôle , Résistance microbienne aux médicaments
SÉLECTION CITATIONS
Détails de la recherche